REVB (Revelation Biosciences) Inventories, Inventories Adjustments: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

REVB Revelation Biosciences Inc REVB
28 GF Score
Price $1.09
! 1 Warning Sign
View Full Analysis

What is Revelation Biosciences Inventories, Inventories Adjustments?

Revelation Biosciences REVB 28 Inventories, Inventories Adjustments is $0.00 Mil as of Jun. 2026. GuruFocus rates REVB with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

Revelation Biosciences's Inventories, Inventories Adjustments for the quarter that ended in Jun. 2026 was $0.00 Mil.

Revelation Biosciences Inventories, Inventories Adjustments Historical Data

* Premium members only.

The historical data trend for Revelation Biosciences's Inventories, Inventories Adjustments can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Revelation Biosciences Inventories, Inventories Adjustments Chart

Revelation Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Inventories Adjustments
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Revelation Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Inventories, Inventories Adjustments Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
REVB
28GF Score
Revelation Biosciences Inc REVB
Inventories, Inventories Adjustments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Revelation Biosciences Inventories, Inventories Adjustments Calculation

Inventories, Inventories Adjustments represents certain charges made in the current period in inventory resulting from breakage, spoilage, employee theft and shoplifting, etc.

What does a Inventories, Inventories Adjustments of $0.00 Mil mean?
Revelation Biosciences (REVB) has a Inventories, Inventories Adjustments of $0.00 Mil as of Jun. 2026. Inventories, Inventories Adjustments is certain charges made in the current period in inventory resulting from breakage, spoilage, etc. View historical data on Revelation Biosciences and its competitors.
Is Revelation Biosciences' Inventories, Inventories Adjustments too high?
Revelation Biosciences' current Inventories, Inventories Adjustments is $0.00 Mil. Overall, Revelation Biosciences has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Revelation Biosciences' Inventories, Inventories Adjustments compare to ELAB and ENSC?
Revelation Biosciences' Inventories, Inventories Adjustments of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Inventories Adjustments for a Biotechnology company?
A good Inventories, Inventories Adjustments depends on the Biotechnology industry context. However, Inventories, Inventories Adjustments should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Inventories Adjustments mean?
A high Inventories, Inventories Adjustments can signal that a stock is expensive relative to its fundamentals. Inventories, Inventories Adjustments is certain charges made in the current period in inventory resulting from breakage, spoilage, etc. View historical data on Revelation Biosciences and its competitors. Revelation Biosciences's current Inventories, Inventories Adjustments is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revelation Biosciences stock overvalued right now?
Revelation Biosciences (REVB) has a current Inventories, Inventories Adjustments of $0.00 Mil. The current Inventories, Inventories Adjustments is $0.00 Mil. Revelation Biosciences' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Inventories Adjustments calculated?
Inventories, Inventories Adjustments is calculated from a company's financial statements. For Revelation Biosciences (REVB), the current Inventories, Inventories Adjustments is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Revelation Biosciences Business Description

Address 4660 La Jolla Village Drive, Suite 100, San Diego, CA, USA, 92122
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.
28GF Score

Get the complete analysis for REVB

Inventories, Inventories Adjustments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.09
Price